Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest Graft-versus-host disease Stories

2013-06-26 04:20:57

AMSTERDAM, The Netherlands, June 26, 2013 /PRNewswire/ -- Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it will receive an innovation credit of up to EUR3 million from AgentschapNL, a division of the Dutch Ministry of Economic Affairs, to support the Phase II clinical development of Kiadis Pharma's lead pipeline product, ATIR(TM). Kiadis Pharma is currently conducting a Phase II international...

2013-05-30 13:43:03

Stem Cell Matrix -- a summary of recent studies from HSCI May brought a major advancement in the science of aging when two Harvard Stem Cell Institute (HSCI) researchers announced their discovery of a protein circulating in the blood of mice and humans that shows potential to be a treatment for age-related heart failure. The protein, called GDF-11, reduced the size and thickness of the heart walls when injected into old mice. There are hundreds of investigators in the HSCI network...

2013-04-04 08:29:53

Major milestone achieved as orphan status grants Enlivex seven years of exclusivity for treatment based on immune tolerance for GVHD JERUSALEM, April 4, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that one of its flagship portfolio companies, Enlivex...

2013-03-14 12:27:50

WASHINGTON, March 14, 2013 /PRNewswire-USNewswire/ -- Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler's syndrome (HS), according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). HS is an inherited metabolic disease characterized by the lack of a critical...

2013-02-13 12:25:39

In the news release, The Expected Approval of Velcade Will Be a Significant Driver of Growth in the Graft Versus Host Disease Drug Market, issued 07-Feb-2013 by Decision Resources over PR Newswire, we are advised by the company that there have been several revisions to the release. The complete, corrected release follows: Physicians' Adoption of Velcade for the Treatment of Chronic Graft Versus Host Disease Will Drive Growth In This Market Through 2021 Uptake of Velcade in the First-Line...

2013-02-07 12:25:08

BURLINGTON, Mass., Feb. 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the expected supplemental approval of Millennium (Takeda)/Johnson & Johnson's Velcade for the treatment of chronic graft versus host disease (GVHD) will be a significant driver of growth in the GVHD market through 2021. In particular, Velcade's uptake in the first-line treatment setting will displace lower-priced...

2012-12-11 12:01:29

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting. The combination of two immunosuppressive compounds -- tacrolimus plus sirolimus -- did not provide a statistically significant, GVHD-free survival benefit over the long-used standard of care, tacrolimus plus methotrexate, said researchers from...

2012-12-10 16:44:50

Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. Hematopoietic stem cell transplantation is effectively used today as a form...

2012-12-10 16:43:16

First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center. The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant,...

2012-12-09 12:20:12

ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. Hematopoietic stem cell...